Study details first artificial intelligence tool to help labs rule-out COVID-19

This scanning electron microscope image shows SARS-CoV-2 (yellow)—also known as 2019-nCoV, the virus that causes COVID-19—isolated from a patient, emerging from the surface of cells (blue/pink) cultured in the lab. Credit: NIAID-RML

Hospital-based laboratories and doctors at the front line of the COVID-19 pandemic might soon add artificial intelligence to their testing toolkit. A recent study conducted with collaborators from the University of Vermont and Cedars-Sinai describes the performance of Biocogniv’s new AI-COVID software. The team found high accuracy in predicting the probability of COVID-19 infection using routine blood tests, which can help hospitals reduce the number of patients referred for scarce PCR testing.

Their study in the Journal of Medical Internet Research is available online.

“Nine months into this pandemic, we now have a better understanding of how to care for patients with COVID-19,” says lead author and University of Vermont Assistant Professor Timothy Plante, M.D., M.H.S., “but there’s still a big bottleneck in COVID-19 diagnosis with PCR testing.”

PCR testing is the current standard diagnostic for COVID-19, and requires specific sampling, like a nasal swab, and specialized equipment to run.

Biocogniv Chief Operating Officer Tanya Kanigan, Ph.D., says, “According to data from over 100 US hospitals, the national average turnaround time for COVID-19 tests ordered in emergency rooms is above 24 hours, far from the targeted one-hour turnaround.”

Complete Blood Count and Complete Metabolic Panels are common laboratory tests ordered by emergency departments and have a rapid turnaround time. These tests provide insight into the immune system, electrolytes, kidney, and liver. The researchers were able to train a model that analyzes changes in these routine tests and assigns a probability of the patient being COVID-19 negative with high accuracy.

“AI-COVID takes seconds to generate its informative result once these blood tests return, which can then be incorporated by the laboratory into its own test interpretation,” says Jennifer Joe, M.D., an emergency physician in Boston, Mass. and Biocogniv’s Chief Medical Officer. “In an efficient that prioritizes these routine blood tests, the door-to-result time could be under an hour.”

Cedars-Sinai pulmonary and internal medicine specialist Victor Tapson, M.D., says such assistive tools that help physicians rule out possible diagnoses are familiar in emergency medicine.

“For example, a low D-dimer blood can help us rule out clots in certain patients, allowing providers to skip expensive, often time-consuming diagnostics such as chest CT scans,” says Tapson.

The Biocogniv team believes a secondary benefit of laboratories incorporating AI-COVID might be reduced time for traditional PCR results.

“With the help of AI-COVID, laboratories might relieve some of the testing bottleneck by helping providers better allocate rapid PCR testing for patients who really need it,” says Joe.

The AI-COVID model was validated on real world data from Cedars-Sinai as well as on data from geographically and demographically diverse patient encounters from 22 U.S. hospitals, achieving an area under the curve (or AUC) of 0.91 out of 1.00.

“This enables the model to achieve a high sensitivity of 95% while maintaining moderate specificity of 49%, which is very similar to the performance of other commonly used rule-out tests,” says Biocogniv Chief Scientific Officer George Hauser, MD, a pathologist.

Biocogniv CEO Artur Adib, Ph.D., says, “I’m honored to have such an impressive team of medical scientists from the University of Vermont and Cedars-Sinai as collaborators in validating this timely model. AI has progressed considerably; the time is now to leverage this powerful tool for new healthcare breakthroughs, and we’re glad to direct it to help hospital laboratories and providers combat the current COVID-19 crisis.”


Follow the latest news on the coronavirus (COVID-19) outbreak


More information:
Timothy B Plante et al, Development and External Validation of a Machine Learning Tool to Rule Out COVID-19 Among Adults in the Emergency Department Using Routine Blood Tests: A Large, Multicenter, Real-World Study, Journal of Medical Internet Research (2020). DOI: 10.2196/24048

Provided by
Larner College of Medicine at the University of Vermont

Citation:
Study details first artificial intelligence tool to help labs rule-out COVID-19 (2020, December 10)
retrieved 10 December 2020
from https://medicalxpress.com/news/2020-12-artificial-intelligence-tool-labs-rule-out.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.





Source link

Health News

Aromatherapy spray linked to US deaths faces recall

This undated photo provided by Walmart and the U.S. Centers for Disease Control and Prevention shows a bottle of Better Homes & Gardens aromatherapy lavender & chamomile essential oil and semiprecious stone-infused room spray. The Consumer Product Safety Commission and Walmart issued a recall Friday, Oct. 22. 2021, for 3,900 bottles of the spray. Credit: Walmart/CDC […]

Read More
Health News

mRNA vaccine more effective booster to ChAdOx1 nCoV-19

(HealthDay)—Use of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination is more effective than homologous ChAdOx1 nCoV-19/ChAdOx1 nCoV-19 prime-boost vaccination, according to a study published online Oct. 17 in The Lancet Regional Health: Europe. Peter Nordström, M.D., Ph.D., from Umeå University in Sweden, and colleagues examined the effectiveness of heterologous prime-boost COVID-19 vaccination among individuals in […]

Read More
Health News

Moving monoclonal antibody treatments for COVID from hospital to home

(HealthDay)—Antibody infusions help keep high-risk COVID-19 patients out of the hospital, but getting the therapy can be a challenge. One U.S. health system has found a creative way to address the problem: home infusions administered by paramedics. They delivered antibody infusions to 144 COVID-19 patients in their homes over three months earlier this year. Most—about […]

Read More